Amycretin vs Eloralintide
GLP-1 and amylin agonism combined in a single molecule, not a two-drug combination. A selective, long-acting amylin agonist that reaches GLP-1-class weight loss without touching the GLP-1 receptor. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Amycretin | Eloralintide | |
|---|---|---|
| Also known as | — | — |
| Type | Analog | Analog |
| Evidence | Investigational | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Unimolecular GLP-1 + amylin receptor agonist (peptide) | Selective long-acting amylin analog (acylated 37 aa peptide) |
| Receptor / target | GLP-1 receptor + amylin receptors | Amylin receptors (calcitonin receptor + RAMP), AMY1-selective |
| Molecular weight | ≈7,900 Da | ~4,526 Da |
| Half-life | ~days (weekly SC dosing) | |
| Based on | Amylin | Amylin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Amycretin and Eloralintide?
- Amycretin is an engineered analog based on Amylin; Eloralintide is an engineered analog based on Amylin. Amycretin signals at GLP-1 receptor + amylin receptors; Eloralintide signals at Amylin receptors (calcitonin receptor + RAMP), AMY1-selective.
- How do the half-lives of Amycretin and Eloralintide compare?
- The reported circulating half-life of Amycretin is ~days (weekly SC dosing); Eloralintide is ~13–15 days (310–366 h). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Eloralintide vs Amycretin. Or open the interactive comparison tool to add more molecules.